An interesting possible target for the implementation of an efficacious immunotherapy of MM is the B-cell maturation antigen (BCMA), a component of the tumor necrosis factor (TNF) receptor superfamily and the receptor for linking of B-cell activating factor (BAFF) and the proliferation-inducing ligand (APRIL). This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.